Published on 22/12/2025
Oncology Basket Trials in the United States: Regulatory Framework, Design, and Best Practices
Introduction
Basket trials have emerged as a transformative approach in oncology, allowing the evaluation of a single therapy across multiple tumor types that share a common biomarker or molecular alteration. In the United States, the Food and Drug Administration (FDA) has embraced basket trials as part of its precision medicine strategy, particularly in oncology. These innovative designs enable accelerated evaluation of targeted therapies, often leading to tumor-agnostic approvals. However, basket trials present operational, statistical, and regulatory challenges that sponsors must navigate. This article examines the regulatory framework, trial design considerations, FDA expectations, and case studies related to oncology basket trials in the U.S.
Background / Regulatory Framework
FDA’s Role in Basket Trials
The FDA recognizes basket trials as critical tools for precision oncology. Regulatory guidance emphasizes the need for robust biomarker validation, appropriate statistical methods, and careful interpretation of subgroup analyses. Basket trials often support Breakthrough Therapy designations, Accelerated Approvals, or Priority Reviews, particularly for rare mutations where traditional trial designs are impractical.
ICH and Global Perspectives
While ICH guidelines do not provide specific provisions for basket trials, principles of Good
Case Example—Pembrolizumab Approval
Pembrolizumab (Keytruda) became the first FDA-approved tumor-agnostic therapy based on a basket trial demonstrating efficacy in microsatellite instability-high (MSI-H) and mismatch repair-deficient (dMMR) cancers, regardless of tumor origin. This landmark approval validated basket trials as a viable regulatory pathway.
Core Clinical Trial Insights
1) Trial Design and Objectives
Basket trials test one investigational therapy across multiple tumor types defined by a shared biomarker. Objectives may include preliminary efficacy in rare cancers, expansion cohorts for common tumors, or confirmation of tumor-agnostic efficacy. FDA expects prespecified statistical plans and robust biomarker validation.
2) Patient Recruitment Challenges
Recruitment relies heavily on genomic screening to identify eligible patients. FDA expects transparent criteria and emphasizes inclusion of diverse populations. Collaborations with molecular testing companies and cancer centers are essential for success.
3) Statistical Considerations
Each tumor-specific cohort may be analyzed independently or pooled if scientifically justified. FDA requires careful control of type I error, especially when multiple cohorts are tested simultaneously. Adaptive designs may allow expansion or termination of cohorts based on interim results.
4) Biomarker Validation
FDA requires robust analytical and clinical validation of biomarkers used to define eligibility. Assays must be reproducible, clinically meaningful, and validated under CLIA standards. Biomarker misclassification is a major regulatory risk in basket trials.
5) Regulatory Interactions
Sponsors benefit from early FDA engagement through pre-IND and End-of-Phase 2 meetings. Type C meetings provide opportunities to discuss innovative statistical designs, biomarker strategies, and accelerated approval pathways.
6) Role in Rare Diseases and Orphan Cancers
Basket trials are particularly valuable for rare mutations, where standalone trials are unfeasible. FDA often accepts smaller sample sizes in rare subgroups if the therapeutic effect is compelling and supported by robust biomarker rationale.
7) Operational Complexity
Managing multiple cohorts across tumor types requires complex logistics, including central genomic screening, diverse site networks, and multiple protocol amendments. FDA expects sponsors to demonstrate strong oversight and documentation of protocol deviations.
8) Ethics and Patient Considerations
Basket trials offer patients with rare cancers access to investigational therapies otherwise unavailable. However, ethical considerations include informed consent clarity, equitable access, and risk-benefit balance for underrepresented populations.
9) CRO and Vendor Involvement
CROs play a critical role in managing basket trials, including genomic testing partnerships, data management, and adaptive trial logistics. Sponsors must qualify CROs thoroughly and maintain oversight to meet FDA expectations.
10) FDA Inspections and Data Integrity
FDA inspections of basket trials focus on protocol adherence, biomarker testing accuracy, and data consistency across cohorts. Sponsors must ensure electronic systems are validated and data traceability is maintained.
Best Practices & Preventive Measures
Sponsors should: (1) validate biomarkers early; (2) engage FDA proactively; (3) adopt adaptive statistical designs; (4) harmonize global trial protocols; (5) ensure robust genomic screening partnerships; (6) maintain TMF documentation for all cohorts; (7) provide investigator training on eligibility criteria; (8) address diversity in recruitment; and (9) implement robust oversight of CROs and vendors.
Scientific & Regulatory Evidence
Key references include FDA guidance on clinical trial endpoints in oncology (2018), FDA’s Expedited Programs Guidance (2014), 21 CFR Part 312, ICH E6(R2) GCP, and published case studies on pembrolizumab and larotrectinib approvals. These documents provide the regulatory foundation for basket trials in the U.S.
Special Considerations
Pediatric oncology basket trials, rare mutations, and immunotherapy combinations pose unique design and ethical challenges. FDA encourages sponsors to collaborate with pediatric oncology groups and patient advocacy organizations when designing such trials.
When Sponsors Should Seek Regulatory Advice
Sponsors should consult FDA before launching basket trials to confirm biomarker rationale, statistical design, and regulatory pathways. Pre-IND and End-of-Phase 2 meetings are critical for aligning expectations and avoiding costly delays.
Case Studies
Case Study 1: Larotrectinib Approval
Larotrectinib received FDA tumor-agnostic approval based on basket trials targeting NTRK gene fusions across multiple cancers. The small but compelling dataset demonstrated the power of basket trial design for rare mutations.
Case Study 2: Rare Mutation Basket Trial
A sponsor conducted a basket trial for a targeted therapy in multiple rare cancers with BRAF mutations. FDA granted Breakthrough Therapy designation, accelerating approval despite small sample sizes.
Case Study 3: Basket Trial Operational Failure
An oncology basket trial failed due to inadequate biomarker testing and inconsistent eligibility criteria across sites. FDA rejected the data package, underscoring the importance of biomarker validation and operational oversight.
FAQs
1) What is a basket trial in oncology?
A trial evaluating one drug across multiple tumor types sharing a common biomarker or molecular alteration.
2) Does FDA accept data from basket trials?
Yes, if biomarkers are validated, endpoints are clinically meaningful, and statistical methods are robust.
3) What cancers are commonly studied in basket trials?
Oncology basket trials often target biomarker-defined cancers such as MSI-H, NTRK fusions, and BRAF mutations.
4) How do basket trials differ from umbrella trials?
Basket trials test one therapy across different cancers, while umbrella trials test multiple therapies within one cancer type.
5) What are FDA’s main concerns with basket trials?
Biomarker misclassification, small sample sizes, type I error inflation, and operational inconsistencies.
6) Are basket trials commonly used in rare diseases?
Yes, basket trials are particularly useful in rare mutations where standalone trials are impractical.
7) Can basket trials lead to accelerated approvals?
Yes, basket trials often support Accelerated Approval or Breakthrough Therapy designation for oncology drugs.
Conclusion & Call-to-Action
Oncology basket trials are reshaping precision medicine in the United States, enabling tumor-agnostic approvals and faster access to innovative therapies. Sponsors must validate biomarkers, adopt rigorous statistical methods, and maintain strong regulatory engagement with FDA. By addressing operational challenges and ensuring data integrity, sponsors can leverage basket trials to transform oncology drug development and deliver new hope to patients across multiple tumor types.